FDA Approved: LAMICTAL XR — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approved a supplemental application for LAMICTAL XR (lamotrigine) from GlaxoSmithKline LLC, authorizing changes to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• LAMICTAL XR (lamotrigine)

Snippet

SUPPL AP for LAMICTAL XR (LAMOTRIGINE)